QUALITY IMPROVEMENT


The Story Behind a Complex


still contracting the virus and at risk; some people can’t be vaccinated or missed getting vaccinated; occasionally, someone doesn’t develop immunity. What was true at the beginning of the


D


pandemic is still true more than a year later: Older adults are at a far greater risk of hospitalization and death as a result of coronavirus. But there’s a treatment that has had life-


saving effects: Monoclonal antibody treat- ments, or mAb. Studies show that when ad- ministered early in the course of infection, these outpatient infusions are 87 percent effective in impeding disease progression and preventing hospitalizations. It’s not a cure, but it far minimizes the complications and seriousness of a case of COVID-19 and helps lead the body to recovery. “Preventing hospitalizations”—that’s a


top goal for senior living, particularly during the pandemic, when a hospitalization can leave a resident at risk of further infections, isolated, stressed, and worse. Another key phrase is “administered


early”—treatment should be administered as soon as possible after symptoms start in order to be successful. This requires a test with a short turn-around time. Antibodies cannot be given more than 10 days after symptoms start. But mAb treatment requires specialized


procedures, training, knowledge, and access to the medication itself. These are not typi- cally available in a senior living community. And a senior living staff handling highly de- manding work during a pandemic simply doesn’t have the capacity to stretch that far. That’s where public-private partnerships


24 SENIOR LIVING EXECUTIVE MAY/JUNE 2021


espite the apparent success of vac- cination, the COVID-19 danger is by no means over. People are


leapt in to fill the gap. The goal was to have trained assistance, pharmacies, and community capabilities converge ASAP to deliver treatments—riding to the rescue, so to speak.


What is mAb treatment? Monoclonal antibodies are antibodies made in the lab. They’re modeled after natural antibodies, then customized to attack spe- cific threats. When mAbs made to attack COVID-19 are given to a person testing positive for COVID-19, they home in on the spike proteins on the virus—those spiky bumps you see on the pictures of enlarged viruses posted seemingly everywhere—and wipe them out. Different types of monoclonal antibod-


ies target different spikes; recently, using a combination of types was found to be more effective. Changes in the types of antibodies and combinations used are ongoing with the


But Lifesaving COVID-19 Treatment By Sara Wildberger


requires significant documentation—prov- ing eligibility and consents—and prepara- tion that must be followed to the letter. It requires special handling. Obviously,


lab-made products need special handling to be used safely. The mAb treatments themselves had to get to pharmacies serv- ing long-term care communities, and then to communities, all according to procedures. It requires special skills. The treatment


is done by infusion, and infusion requires training and expertise, usually from a regis- tered nurse. The professional administering the treatment needs to be able to insert an IV and observe and assist as needed during the one-hour infusion time. The professional also must monitor the


patient for an hour after the infusion. But assisted living settings often don’t have in- fusion professionals. And if a patient has to go to the hospital to receive mAb treatment, it defeats the purpose.


“I think something we do quite well is partner very closely with the medical entities around us and coordinate resources. I encourage other senior living providers to not think they can do it all on their own,” says Meredith Mills, senior vice president and COO at Country Meadows.


emergence of variants and new research. Before senior living residents could bene- fit from mAb treatment, several obstacles needed to be overcome. It's new. In November 2020, mAb treat-


ments were authorized by the U.S. Food and Drug Administration, under an emergency use authorization (EUA). But an EUA status


It sometimes requires education. As with


all action around COVID-19, using these treatments means helping residents and fam- ilies get a clear and accurate understanding. Getting permissions and handling billing and reimbursement can be complicated as well. But with lives at stake, solutions soon abounded.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52